BASKING RIDGE, N.J. — Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced the publication of a case report detailing a complete response in a patient with metastatic gastroesophageal adenocarcinoma patient treated with LSTA1 in combination...
research News
BASKING RIDGE, N.J. — Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced treatment of the first patient in a Phase 2a trial evaluating LSTA1 in patients with newly diagnosed glioblastoma multiforme (“GBM”). The trial is...
LncRNA DLGAP1-AS2 is overexpressed in patients with non-small cell lung cancer (NSCLC) and may promote cell proliferation by upregulating cyclin D1 by sponging miR-503, according to a study published in BMC Pulmonary Medicine. Effective targets for lung cancer remain lacking. However, it has been suggested that lncRNAs and miRNAs are promising...
LEXINGTON, Mass. – LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced results from a retrospective study of the disease course in pediatric patients living with severe methylmalonic acidemia (MMA) caused...
North Bethesda, Maryland – Long-acting antiretroviral therapy (ART) with cabotegravir and rilpivirine was superior in suppressing HIV replication compared to daily oral ART in people who had been unable to maintain viral suppression through an oral daily regimen, according to interim data from a randomized trial. Upon review of these...
Nijmegen, Netherlands – The cause of rare diseases is increasingly being detected through genome sequencing, which involves reading the entire human DNA by first breaking it into small pieces—short reads. Christian Gilissen, Lisenka Vissers, and colleagues found that a new technique using long reads is even more effective at detecting...
Nashville, Tennessee – A 10-year follow up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision making in terms of treatments and side effects for a diverse population. The CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation for Localized Prostate Cancer) study, coordinated by...
Cleveland, Ohio – Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab. These long-term results from the S1318 clinical trial...
London, UK – A highly sensitive bone marrow test could double survival rates for some groups of younger adults with Acute Myeloid Leukaemia (AML) by helping doctors identify if they might relapse up to three months earlier. The patient-specific molecular test can detect low levels of leukaemia cells in the...
Tokyo, Japan – Researchers from Tokyo Metropolitan University have studied pancreatic islet cell loss in people with no previous pancreatic problems. They identified key trends in the types of cells lost due to islet cell loss in different age groups and sexes, finding that ICL in the elderly population was...